::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

SALBUTAMOL IN CONTROLLING ASTHMA

AUTHORS:

Dr Umar Hameed, Dr Muhammad Umer Saeed, Dr Ali Hassan

ABSTRACT:

Salbutamol is an adrenergic receptor agonist of short-acting beta2 used in the treatment of asthma and COPD. Salbutamol reactions are proprietary and particularly effective if used correctly. In the treatment of asthma salbutamol: nebuliser / inhaler and preventive medicines in the treatment of dose-metric asthma (pMDI), nebulizer or a dry powder inhaler to use. It is also used prophylactically to treat induced asthma. Salbutamol is used to reduce the side effects of asthma and COPD, such as: B. Cut, wheeze, and shortness of breath. The greatest improvement in lung capacity usually occurs 60 to 1.5 hours after treatment with salbutamol, and the bronchodilator movement has been found to last for 3 to 6 hours. Salbutamol, with its beneficial effects on relaxing the smooth muscles of the airways and expanding the flow of air, quickly helps with the serious side effects of asthma. Part Salbutamol beta agonists in asthma control short-acting (Saabs, such as Salbutamol, as a first-line therapy for the treatment of severe seizures, initiated to treat asthma, and Persistent Asthma in Adolescents, Salbutamol is usually transmitted through the intravenous salbutamol when young people are breathing inertia during treatment. Salbutamol is commonly used in extreme bronchial asthma scenes with incessant bronchitis and other chronic bronchopulmonary complications, such as continuous pulmonary obstructions (COPD).